Holen Sie sich die Stockscreener-App
3.35
3.18%
-0.11
Handel nachbörslich:
3.35
Schlusskurs vom Vortag:
$3.46
Offen:
$3.46
24-Stunden-Volumen:
405.77K
Relative Volume:
1.17
Marktkapitalisierung:
$175.60M
Einnahmen:
$17.63M
Nettoeinkommen (Verlust:
$-57.71M
KGV:
-2.5188
EPS:
-1.33
Netto-Cashflow:
$-60.45M
1W Leistung:
-20.80%
1M Leistung:
-26.05%
6M Leistung:
-29.47%
1J Leistung:
-36.19%
1-Tages-Spanne:
$3.31
$3.54
1-Wochen-Bereich:
$3.075
$4.23
52-Wochen-Spanne:
$3.075
$6.71
Scpharmaceuticals Inc Stock (SCPH) Company Profile
Firmenname
Scpharmaceuticals Inc
Sektor
Branche
Telefon
858-952-5500
Adresse
505 COAST BOULEVARD SOUTH, LA JOLLA, MA
Vergleichen Sie SCPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SCPH | 3.35 | 175.60M | 17.63M | -57.71M | -60.45M | -1.33 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-01 | Eingeleitet | Cowen | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-10-11 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-02 | Eingeleitet | Maxim Group | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-30 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
Alle ansehen
Scpharmaceuticals Inc Aktie (SCPH) Neueste Nachrichten
King Luther Capital Management Corp's Strategic Acquisition in scPharmaceuticals Inc - GuruFocus.com
Earnings Update: scPharmaceuticals Inc. (NASDAQ:SCPH) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance Australia
scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2024 Earnings Call Transcript - Insider Monkey
The one-year earnings decline has likely contributed toscPharmaceuticals' (NASDAQ:SCPH) shareholders losses of 33% over that period - Simply Wall St
Earnings call: scPharmaceuticals reports robust Q3 growth, eyes FDA nod By Investing.com - Investing.com UK
ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates - MSN
scPharmaceuticals Inc (SCPH) Q3 2024 Earnings Call Highlights: R - GuruFocus.com
scPharmaceuticals Inc (SCPH) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
scPharmaceuticals Reports Strong Growth in Q3 2024 - TipRanks
ScPharmaceuticals Q3 Loss Widens, Revenue Rises - Marketscreener.com
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
scPharmaceuticals' FUROSCIX Revenue Surges 164% YoY to $10M in Q3, Expands FDA Approval | SCPH Stock News - StockTitan
Certain Common Stock of scPharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2024. - Marketscreener.com
scPharmaceuticals (SCPH) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 - The Manila Times
scPharmaceuticals Sets Q3 2024 Earnings Call for November 13 | SCPH Stock News - StockTitan
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
KING LUTHER CAPITAL MANAGEMENT CORP Expands Stake in scPharmaceu - GuruFocus.com
TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval - Investing.com India
TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval By Investing.com - Investing.com South Africa
Third Time's The Charm For ScPharma? - RTTNews
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 - GlobeNewswire
Congestive Heart Failure Treatment Market 2034: Clinical - openPR
The Attractiveness of Investing In scPharmaceuticals Inc (SCPH) is Growing - Knox Daily
Daily Progress: scPharmaceuticals Inc (SCPH) Drop -2.33, Closing at 3.97 - The Dwinnex
scPharmaceuticals GAAP EPS of -$0.41 misses by $0.05, revenue of $3.8M beats by $0.38M - MSN
Does scPharmaceuticals (SCPH) Have the Potential to Rally 291.9% as Wall Street Analysts Expect? - MSN
351,806 Shares in scPharmaceuticals Inc. (NASDAQ:SCPH) Acquired by Bank of Montreal Can - MarketBeat
scPharmaceuticals Inc. (NASDAQ:SCPH) Short Interest Down 15.0% in September - MarketBeat
Holdings of scPharmaceuticals Inc (SCPH) are aligned with the stars - SETE News
Craig Hallum gives a Buy recommendation for scPharmaceuticals Inc (SCPH) - Knox Daily
King Luther Capital Management Corp Purchases 752,005 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
Investors in scPharmaceuticals (NASDAQ:SCPH) have unfortunately lost 23% over the last year - Yahoo Finance
Rice Hall James & Associates LLC Has $2.16 Million Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
scPharmaceuticals Inc [SCPH] Investment Guide: What You Need to Know - Knox Daily
scPharmaceuticals Inc. (NASDAQ:SCPH) Stock Holdings Increased by AIGH Capital Management LLC - MarketBeat
scPharmaceuticals Inc [SCPH] 10% Owner makes an insider purchase of 500,000 shares worth 2.0 million. - Knox Daily
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
scPharmaceuticals’ $125 Million Senior Secured Term Loan - Global Legal Chronicle
Do investors need to be concerned about scPharmaceuticals Inc (SCPH)? - US Post News
There is no way scPharmaceuticals Inc (SCPH) can keep these numbers up - SETE News
scPharmaceuticals Inc (SCPH) rating initates by Craig Hallum - Knox Daily
Assenagon Asset Management S.A. Boosts Stake in scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
scPharmaceuticals Inc. to Post Q3 2024 Earnings of ($0.28) Per Share, HC Wainwright Forecasts (NASDAQ:SCPH) - MarketBeat
Craig Hallum’s latest rating for SCPH stock - Knox Daily
After losing 35% in the past year, scPharmaceuticals Inc. (NASDAQ:SCPH) institutional owners must be relieved by the recent gain - Yahoo Finance
scPharmaceuticals (NASDAQ:SCPH) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
scPharmaceuticals stock rated a Buy amid revenue growth - Investing.com
scPharmaceuticals (FRA:2SX) Inventory-to-Revenue : 1.54 (As of Jun. 2024) - GuruFocus.com
Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings - BioCentury
scPharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Finanzdaten der Scpharmaceuticals Inc-Aktie (SCPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):